Tag: 200-300

On May 7, 1998, Ankersen, Michael; Dorwald, Florenzio Zaragoza; Stidsen, Carsten Enggaard; Crider, Albert Michael published a patent.Product Details of 199522-66-2 The title of the patent was Preparation of thiourea derivatives and related compounds as constrained somatostatin agonists and antagonists. And the patent contained the following:

The title compounds B(CH2)nNA(CH2)mYNR1C(:X)E [I; A = (un)substituted aryl; B = (un)substituted aryl; E = heterocyclyl, amino; R1 = H, (un)substituted C1-6 alkyl; X = S, O, NR3; R3 = H, COPh, cyano; Y = bond, etc.; m = 0-6; n = 0-3], somatostatin agonists and antagonists (no data) useful for treating medical disorders related to binding to human somatostatin receptor subtypes, and their pharmaceutically acceptable salts were prepared and claimed. For example, amination of 2,5-dibromopyridine with H2NCH2CH2NH2 in pyridine gave N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine which was benzylated with 3,4-dichlorobenzyl chloride in DMSO in the presence of NaH and the product condensed with CS2 in the presence of dicyclohexylcarbodiimide in THF to give 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminoethyl isothiocyanate. Addition of the latter with 4-[4(5)-imidazolyl]piperidine-2HCl in THF in the presence of Et3N gave a title compound I. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Product Details of 199522-66-2

The Article related to thiourea derivative preparation somatostatin agonist, imidazolylpiperidinecarbothioic acid bromopyridinyldichlorobenzylaminoethylamide, ethanediamine amination dibromopyridine somatostatin agonist preparation, bromopyridylethanediamine preparation benzylation dichlorobenzyl chloride and other aspects.Product Details of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 31, 2013, Ueno, Hirokazu; Yamamoto, Takashi; Takashita, Ryuta; Yokoyama, Ryohei; Sugiura, Toshihiko; Kageyama, Shunsuke; Ando, Ayatoshi; Eda, Hiroyuki; Eviryanti, Agung; Miyazawa, Tomoko; Kirihara, Aya; Tanabe, Itsuya; Nakamura, Tarou; Noguchi, Misato; Shuto, Manami; Sugiki, Masayuki; Dohi, Mizuki published a patent.Application In Synthesis of 4-Bromo-2-isopropylpyridine The title of the patent was Preparation of N-(4-sulfonamidobenzoyl)-L-phenylalanine and N-(4-sulfonamidobenzoyl)-3-(pyridin-2-yl)-L-alanine derivatives as α4-integrin inhibitors. And the patent contained the following:

There are provided L-phenylalanine and 3-(pyridin-2-yl)-L-alanine derivatives having terminal sulfonamide groups and heterocyclic groups [I; A = Q, Q1, Q2; Arm = cycloalkane or aromatic ring containing 0-4 heteroatoms selected from O, S, and N; R1, R2, R3, R11, R12, R13, R14, R21, R22, R23, R24, R25 = group A, H, lower alkylamino, lower alkylamino-lower alkyl; group A = halo, HO, each hydroxy- or halo-(un)substituted lower alkyl, alkenyl, alkynyl, or alkylthio, NO2, NH2, CO2H, lower alkyloxycarbonyl, CONH2, lower alkanoyl, aroyl, lower alkylsulfonyl, SO2NH2, ammonium group; B = (un)substituted lower alkoxy, HO, hydroxyamino; R41 = H, lower alkyl; a, b, c, d = CR31, CR32, CR33, CR34; e, f, g, h = CR35, CR36, CR37, CR38; R31-R38 = H, halo, lower alkyl, lower alkoxy, NO2; wherein one or two of a, b, c, and d = N atom; one or two of e, f, g, and h = N atom; at least one of R31-R34 = halo or lower alkyl; D = each (un)substituted Ph or heterocyclyl; E = group A, lower alkylaminoalkylene, (un)substituted 5- or 6-membered heterocyclyl, or substituted CONH2; or lower alkylcarbonyl and lower alkyloxycarbonyl in E group are linked to Ph of D group to form a ring] or pharmaceutically acceptable salts thereof. These compounds have excellent α4-integrin-inhibiting activity with high selectivity for α4β7-integrin over α4β1-integrin. They are useful for the treatment or prevention of inflammatory diseases related to α4β7 integrin-dependent adhesion process. Thus, 100 mg Me 4-(1-methyl-2,4-dioxo-1,4-dihydropyrido[3,4-d]pyrimidin-3(2H)-yl)-L-phenylalaninate and 89.0 mg 2,6-difluoro-4-[[[5-(1H-1,2,4-triazol-1-yl)pyridin-2-yl]sulfonyl]amino]benzoic acid were suspended in 2.0 mL CH2Cl2, treated with 133 mg HATU and 0.160 mL diisopropylethylamine, stirred at room temperature for 2 h, and concentrated under reduced pressure to give, after purification using reversed phase HPLC, Me N-[2,6-difluoro-4-([[5-(1H-1,2,4-triazol-1-yl)pyridin-2-yl]sulfonyl]amino)benzoyl]-4-(1-methyl-2,4-dioxo-1,4-dihydropyrido[3,4-d]pyrimidin-3(2H)-yl)-L-phenylalaninate (II; R = Me) tris(trifluoroacetate). II.3CF3CO2H (R = Me) (25.0 mg) was treated with 2.0 mL 4 N HCl/dioxane solution and 2.0 mL H2O, stirred at 80° for 1 h, and concentrated to give, after purification using reversed phase HPLC, II.3CF3CO2H (R = H). II (R = H) (free base) inhibited the binding of MAdCAM to human RPMI-8866 cells expressing α4β7 integrin and that of MAdCAM to human RPMI-8866 cells expressing α4β1 integrin with IC50 of 0.060 and nM, resp., and 220-fold inhibition selectivity for α4β7 integrin. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Application In Synthesis of 4-Bromo-2-isopropylpyridine

The Article related to sulfonamidobenzoylhenylalanine preparation selective alpha 4 beta 7 integrin inhibitor, inflammatory disease treatment prevention sulfonamidobenzoylhenylalanine preparation, sulfonamidobenzoylpyridinylalanine preparation selective alpha 4 beta 7 integrin inhibitor and other aspects.Application In Synthesis of 4-Bromo-2-isopropylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 15, 2014, Ghaffari, Behnaz; Preshlock, Sean M.; Plattner, Donald L.; Staples, Richard J.; Maligres, Peter E.; Krska, Shane W.; Maleczka, Robert E.; Smith, Milton R. published an article.Electric Literature of 1349171-28-3 The title of the article was Silyl Phosphorus and Nitrogen Donor Chelates for Homogeneous Ortho Borylation Catalysis. And the article contained the following:

Ir catalysts supported by ortho-(diisopropylsilyl)(di-p-tolylphosphino)benzene bidentate ligand that contains P- or N-donors, effects ortho-borylations for a range of substituted aromatics E.g., reaction of C6H5CO2Me with bis(pinacolato)diboron (B2pin2) in the presence of 1.25 mol% [Ir(OMe)(cod)]2/ 2.5 mol% (p-tol)2PC6H4-2-(SiHiPr2) in THF at 80° to give 72% yield of Me 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate. The substrate scope is broad, and the modular ligand synthesis allows for flexible catalyst design. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Electric Literature of 1349171-28-3

The Article related to ortho silylphosphinylbenzene tethered iridium cyclooctadiene preparation catalyst orthoborylation, crystal structure ortho silylphosphinylbenzene tethered iridium cyclooctadiene, mol structure ortho silylphosphinylbenzene tethered iridium cyclooctadiene and other aspects.Electric Literature of 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 14, 2003, Adam, Geo; Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas Johannes published a patent.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine The title of the patent was Preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for the treatment of neurological disorders. And the patent contained the following:

This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I; variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders, e.g. Alzheimer’s disease. Three examples of pharmaceutical compositions containing I are included. Ki values for 50 examples of I as metabotropic glutamate receptor antagonists are tabulated, e.g. 0.00135 μM for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preparations of I and many example preparations of intermediates are included. For example, 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol) by refluxing in xylene. For I: X is a single bond or an ethynediyl group; and wherein in case X is a single bond, R1 is H, cyano, halogen, lower alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl, or Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR’R”, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)m; m = 1-4; R’ is H, lower alkyl or C3-C6-cycloalkyl; R” is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or =N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH2)n-C(O)-OR”, -(CH2)n-C(O)-NR’R”, -(CH2)n-SO2-NR’R”, -(CH2)n-C(NH2):NR”, hydroxy, lower alkoxy, lower alkylthio, C3-C6-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR’R”, hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4. The experimental process involved the reaction of 4-Bromo-5-ethyl-2-methylpyridine(cas: 98488-99-4).Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

The Article related to alzheimer disease, anti-alzheimer agents, antipsychotics, biological memory retention defect, cognition enhancers, cognitive disorders, drug delivery systems, homo sapiens, human, metabotropic glutamate receptors role: bsu (biological study, unclassified), biol (biological study) (antagonists), nervous system agents, nervous system disease, psychosis, schizophrenia and other aspects.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Thongpaen, Jompol; Manguin, Romane; Dorcet, Vincent; Vives, Thomas; Duhayon, Carine; Mauduit, Marc; Basle, Olivier published an article in 2019, the title of the article was Visible Light Induced Rhodium(I)-Catalyzed C-H Borylation.Recommanded Product: 1349171-28-3 And the article contains the following content:

An efficient visible light induced Rh(I)-catalyzed regioselective borylation of aromatic C-H bonds is reported. The photocatalytic system is based on a single NHC-Rh(I) complex capable of both harvesting visible light and enabling the bond breaking/forming at room temperature The chelating nature of the NHC-carboxylate ligand was critical to ensure the stability of the Rh(I) complex and to provide excellent photocatalytic activities. Exptl. mechanistic studies evidenced a photooxidative ortho C-H bond addition upon irradiation with blue LEDs, leading to a cyclometalated Rh(III)-hydride intermediate. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Recommanded Product: 1349171-28-3

The Article related to rhodium imidazolylidenecarboxylate carbene complex preparation catalyst borylation arene, crystal structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, mol structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, carbon hydrogen activation kinetics borylation arylpyridine rhodium carbene catalyst and other aspects.Recommanded Product: 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 30, 1998, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Application of 199522-66-2 The title of the patent was Preparation of thioureas as somatostatin agonists and antagonists for treating diseases related to the eye. And the patent contained the following:

The title compounds [I; m = 2-6; n = 1-3; p = 1-6; R1, R2 = H, (un)substituted C1-6 alkyl; X = S, O, NH, NCOPh, N(CN); A, B, D = (un)substituted aryl, heteroaryl], somatostatin receptor ligands of nonpeptide origin which have high and/or selective affinity to the somatostatin receptor protein designated SSTR4 (no data), and are useful for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal such as high intraocular pressure (IOP) and/or deep ocular infections, were prepared and formulated. The diseases which may be treated with compounds I are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. Compounds I are effective at 0.001-50 mg/kg/day. E.g., a 5-step synthesis of II.2HCl, starting with propane-1,3-diamine and 2-bromopyridine, is described. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Application of 199522-66-2

The Article related to thiourea preparation formulation somatostatin agonist antagonist, glaucoma thiourea preparation formulation, eye disease thiourea preparation formulation, keratitis thiourea preparation formulation, iritis thiourea preparation formulation, retinitis thiourea preparation formulation, cataract thiourea preparation formulation and other aspects.Application of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.SDS of cas: 25813-24-5 The title of the patent was Preparation of coumarin thiazolyl derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin thiazolyl derivatives I [R1 is H, halogen, OH, (un)substituted alkoxyl, (un)substituted amino, (un)substituted C1-6-alkyl, (un)substituted heterocycloalkyl; R2 is H, halogen, OH, NO2, CN, N3, thiocyanato, CF3, (un)substituted alkoxyl, (un)substituted amino, (un)substituted carbonyl, or (un)substituted C1-6-alkyl; R3 is H or substituted or unsubstituted C1-6-alkyl; R4 is (un)substituted C1-6-alkyl, (un)substituted aryl or (un)substituted heteroaryl; X is S or O; and, Y is O, NH or NMe] are provided. Thus, DBM-308 (II) was prepared from 3-chlorosalicylaldehyde via cyclocondensation with Et acetoacetate in EtOH containing piperidine to give 3-acetyl-8-chlorocoumarin (III); regioselective bromination with CuBr2 in CHCl3 to give 3-(bromoacetyl)-8-chlorocoumarin (IV); and cyclocondensation with 2-MeOC6H4NHC(:S)NH2 to give II. Methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The antiproliferative activity of II was determined [GI50 = 166 nM; TGI = 247 nM; LC50 = >4,000 nM; IC50 = 0.69 μM vs. N828 cell line (hyperproliferative PKD cells); IC50 = 0.54 μM vs. 3-8C1 cell line (hyperproliferative PKD cells)]. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).SDS of cas: 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.SDS of cas: 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 11, 2016, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.Electric Literature of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Electric Literature of 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.Electric Literature of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

In 1954,Chemische Berichte included an article by Heyns, Kurt; Vogelsang, Gerhard. Application of 857433-67-1. The article was titled 《γ-Pyrones and γ-pyridones. I. The constitution of the hydroxy-γ-pyrones and hydroxy-γ-pyridones》. The information in the text is summarized as follows:

Methylation of kojic acid (I) according to Campbell, et al. (C.A. 44, 4468h), gives 54-65% 5-methoxy-2-hydroxymethyl-4-pyrone (II), m. 165°. Treating 25 g. II in 125 cc. concentrated HNO3 (d. 1.41) 70-80 hrs. at 20° with 25 cc. HNO3 (d. 1.52) and pouring the mixture onto 150 g. ice and 750 cc. H2O give 5-methoxy-4-pyrone-2-carboxylic acid (III), m. 282°, also obtained in 2-g. yield when a strong current of air is passed through 8 g. II in 500 cc. H2O containing 10 g. 10% Pd-C catalyst 30 hrs. at 65° and the pH is adjusted from time to time to 5-6. Heating II with concentrated NH4OH in a pressure bottle gives 75-87% 5-methoxy-2-hydroxymethyl-4-pyridone, m. 173-4°, oxidized with concentrated and fuming HNO3 (5:1) to 70-85% 5-methoxy-4-pyridone-2-carboxylic acid, m. 265°, which, heated with SOCl2, gives 94.5% 4-chloro-5-methoxy-2-pyridine-carbonyl chloride (IV), purified by sublimation in vacuo. Saponification of 39 g. IV in H2O in the presence of a little NaOH gives the free acid (V), m. 209° (Me ester, m. 166-7°). Reduction of 10 g. V in 150 cc. 10% HCl with 10 g. Sn and a small amount of HgCl2 several days at 20°, evaporation of the filtered solution, and precipitation of the Sn with H2S give 81.2% 5-methoxy-2-pyridinecarboxylic acid-HCl (VI), m. 202-3°. Refluxing 4 g. VI with 20 cc. 70% HI 3 hrs., diluting the mixture with 20 cc. H2O, decolorizing it with Na2SO3, and adjusting the pH to 3-4 give 51.2% 5-hydroxy-2-pyridinecarboxylic acid, also obtained in 92-5% yield when 7.5 g. 2-carboxy-5-pyridinesulfonic acid (VII) is heated 1 hr. at 220° with 30 g. NaOH and 6 cc. H2O in a Ni crucible and the solution of the melt in 300 cc. H2O is adjusted to pH 4-5 (Me ester, prepared with MeOH and HCl, m. 191-2°). Heating 80 g. 2-picoline in 400 g. 27% oleum in the presence of 2.5 g. HgCl2 at 220-30° gives 40% 2-methyl-5-pyridinesulfonic acid (VIII), m. above 280°. Adding (1 hr.) 126 g. KMnO4 to 63 g. Na salt of VIII in 1 l. gently boiling H2O gives 46.1% VII, m. 287° (decomposition). The compounds are identified by paper chromatography with BuOH-AcOH-H2O (180:20:50), which gives the following Rf values: III 0.26, I 0.80, 5-hydroxy-4-pyrone-2-carboxylic acid 0.27, 5-hydroxy-2-hydroxymethyl-4-pyridone 0.71, and 5-hydroxy-4-pyridone-2-carboxylic acid 0.30 (0.04% bromocresol green in 50% EtOH and 0.1% FeCl3 solution as developers). The position of the 5-OH group in the pyrone and pyridone derivatives obtained from meconic acid and from I is confirmed (cf. Belonossov, C.A. 45, 5650g). In the experiment, the researchers used Methyl 4-chloro-5-methoxypicolinate(cas: 857433-67-1Application of 857433-67-1)

Methyl 4-chloro-5-methoxypicolinate(cas: 857433-67-1) belongs to pyridine. Pyridine, its benzo and pyridine-based compounds play diverse roles in organic chemistry. As ligands, solvents, and catalysts they facilitate reactions; thus descriptions of these new ligands and their applications abound each year.Application of 857433-67-1

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Application In Synthesis of 3,5,6-Trichloropicolinic acidOn March 30, 2010, Ma, Chun An; Li, Mei Chao; Liu, Yan Na; Xu, Ying Hua published an article in Electrochimica Acta. The article was 《In situ FTIR studies on the electrochemical hydrodechlorination of 3,4,5,6-tetrachloropicolinic acid on Ag cathode》. The article mentions the following:

The electrochem. hydrodechlorination reaction from starting material 3,4,5,6-tetrachloropicolinic acid (3,4,5,6-TCP) to the end product 3,6-dichloropicolinic acid (3,6-DCP) was studied by cyclic voltammetry and in situ FTIR spectroscopy (in situ FTIR). Compared with Cu and glassy C, Ag cathode showed a high electrocatalytic activity for the irreversible reduction process of 3,4,5,6-TCP in NaOH aqueous solution In situ FTIR results suggested that electrochem. hydrodechlorination took place in the 4- or 5-position of 3,4,5,6-TCP on Ag cathode after receiving an electron to get mixed trichloropicolinic acid free radical, which could receive another electron and give 3,5,6-trichloropicolinic acid (3,5,6-TCP) and 3,4,6-trichloropicolinic acid (3,4,6-TCP) at the potential more pos. than -1000 mV afterwards. Finally, 3,5,6-TCP and 3,4,6-TCP were further dechlorinated to produce 3,6-dichloropicolinic acid (3,6-DCP) at the potential more neg. than -1000 mV. Further studies of preparative electrolysis experiments by constant current electrolysis were carried out. The results were in good agreement with those from in situ FTIR studies. In the experimental materials used by the author, we found 3,5,6-Trichloropicolinic acid(cas: 40360-44-9Application In Synthesis of 3,5,6-Trichloropicolinic acid)

3,5,6-Trichloropicolinic acid(cas: 40360-44-9) belongs to pyridine. Pyridine, its benzo and pyridine-based compounds play diverse roles in organic chemistry. As ligands, solvents, and catalysts they facilitate reactions; thus descriptions of these new ligands and their applications abound each year.Application In Synthesis of 3,5,6-Trichloropicolinic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem